Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL284 Target Snapshot

Dipeptidyl peptidase 4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,680Compounds
615Assays
30Approved Drugs
6,482.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Dipeptidyl peptidase 4 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 18 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P27487. Start with type 2 diabetes mellitus, then reuse UniProt P27487 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with type 2 diabetes mellitus, then reuse UniProt P27487 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 18 linked drugs
Open source guide
Disease program
type 2 diabetes mellitus

Dipeptidyl peptidase 4 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 18 linked drugs remain visible in the same block.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALOGLIPTIN BENZOATE, ANAGLIPTIN, BISEGLIPTIN, CARMEGLIPTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 18 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dipeptidyl peptidase 4 as ChEMBL target CHEMBL284, mapped to UniProt P27487. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dipeptidyl peptidase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL284
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P27487
Dipeptidyl peptidase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dipeptidyl peptidase 4 is the right protein anchor across sources, using UniProt P27487 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why type 2 diabetes mellitus is currently framed as approved-linked support. It currently carries 18 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDipeptidyl peptidase 4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP27487
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDipeptidyl peptidase 4
UniProt AccessionP27487
Component TypeProtein
Sequence Length766 aa

Dipeptidyl peptidase 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Dipeptidyl peptidase 4, mapped to UniProt P27487. Sequence length is 766 aa.

Mapped IDP27487
Review nameDipeptidyl peptidase 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Dipeptidyl peptidase 4 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
type 2 diabetes mellitus
18 linked drugs · 18 direct · 18 efficacy
Linked drugALOGLIPTIN BENZOATE
Linked drugANAGLIPTIN
Linked drugBISEGLIPTIN
Linked drugCARMEGLIPTIN
Approved-linked Approved
diabetes mellitus
8 linked drugs · 8 direct · 8 efficacy
Linked drugEVOGLIPTIN
Linked drugGEMIGLIPTIN
Linked drugLINAGLIPTIN
Linked drugOMARIGLIPTIN
Approved-linked Approved
hyperlipidemia
1 linked drug · 1 direct · 1 efficacy
Linked drugSITAGLIPTIN PHOSPHATE
Approved-linked Approved
myocardial infarction
1 linked drug · 1 direct · 1 efficacy
Linked drugSITAGLIPTIN PHOSPHATE
Approved-linked Approved
stroke
1 linked drug · 1 direct · 1 efficacy
Linked drugSITAGLIPTIN PHOSPHATE
Late clinical Phase III
kidney disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugDBPR-108
Linked drugEVOGLIPTIN
Linked drugGEMIGLIPTIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALOGLIPTIN BENZOATE, ANAGLIPTIN, BISEGLIPTIN, CARMEGLIPTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetype 2 diabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

30
Approved
10
Phase III
6
Phase II
3
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC505,748.0
KI704.0
EC504.0
KD26.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL63860 10.52 Ki 0.03 Preclinical
CHEMBL4113723 10.3 IC50 0.05 Preclinical
CHEMBL5914058 10.1 IC50 0.08 Preclinical
CHEMBL98869 10.09 Ki 0.082 Preclinical
CHEMBL5269668 10.05 IC50 0.09 Preclinical
CHEMBL4448186 10.0 IC50 0.1 Preclinical
CHEMBL34062 10.0 IC50 0.1 Preclinical
CHEMBL67279 10.0 IC50 0.1 Clinical
CHEMBL186877 10.0 IC50 0.1 Preclinical
CHEMBL237500 10.0 IC50 0.1 Approved
Distribution

pChEMBL Value Distribution

229
5.0
308
5.5
486
6.0
697
6.5
821
7.0
906
7.5
742
8.0
477
8.5
265
9.0
62
9.5
pChEMBL
Approved Drugs

Approved Drugs

GOSOGLIPTIN
CHEMBL515387
Approved 2016
Properties Compare Identifier
TRELAGLIPTIN
CHEMBL1650443
Approved 2015
Properties Compare Identifier
EVOGLIPTIN
CHEMBL1779710
Approved 2015
Properties Compare Identifier
TRELAGLIPTIN SUCCINATE
CHEMBL2105754
Approved 2015
Properties Compare Identifier
OMARIGLIPTIN
CHEMBL2105762
Approved 2015
Properties Compare Identifier
ALOGLIPTIN
CHEMBL376359
Approved 2013
Properties Compare Identifier
ANAGLIPTIN
CHEMBL1929396
Approved 2012
Properties Compare Identifier
TENELIGLIPTIN
CHEMBL2147777
Approved 2012
Properties Compare Identifier
LINAGLIPTIN
CHEMBL237500
Approved 2011
Properties Compare Identifier
SAXAGLIPTIN ANHYDROUS
CHEMBL385517
Approved 2009
Properties Compare Identifier
VILDAGLIPTIN
CHEMBL142703
Approved 2007
Properties Compare Identifier
SITAGLIPTIN PHOSPHATE
CHEMBL1201174
Approved 2006
Properties Compare Identifier
SITAGLIPTIN
CHEMBL1422
Approved 2006
Properties Compare Identifier
VIDARABINE
CHEMBL1090
Approved 1976
Properties Compare Identifier
Assay Landscape

Assay Landscape

616
Total Assays
4,615
Tested Compounds
3
Assay Types
Binding — 566 assays, 4,615 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 431 3,490 7.2
cell-based format 68 476 7.3
assay format 41 407 7.3
cell-free format 26 242 7.3
ADME — 40 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 40 0 —
Functional — 10 assays, 37 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 4 0 —
cell-based format 3 4 6.4
assay format 2 33 6.4
cell-free format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine